Abstract: This invention relates to methods and compositions for assessing an amount of cancer-specific nucleic acids in a sample, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as cancer, in a subject.

Abstract: A swallow exerciser device that exercises and thereby strengthens the muscles involved in swallowing includes a rigid shell, an adjustable fastener, and an inflatable pad. The rigid shell has a longitudinal dimension such that the shell extends above and below the larynx of the subject when the swallow exerciser device is positioned over the larynx of the subject. The adjustable fastener is dimensioned to secure the shell around a neck of the subject with the shell positioned over the larynx of the subject. The inflatable pad is connected to a proximal surface of the shell. The inflatable pad is dimensioned to apply resistance to force of at least one swallowing muscle of the subject when the shell positioned over the larynx of the subject and when the inflatable pad is in an inflated position. The swallow exerciser device can be used in a method for improving swallowing function in a subject.

Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.

Abstract: An esophageal device is used to recognize, diagnose, characterize, or relieve an impact of an abnormal or defective UES anatomy, physiology, or functionality. In one implementation, the esophageal device measures a UES response to esophageal fluid infusion to detect or characterize an abnormality or defective UES anatomy, physiology, or functionality. An Upper Esophageal Sphincter compression device is used to increase intra-luminal pressure within the Upper Esophageal Sphincter of a patient in order relieve an impact of an abnormal or defective UES anatomy, physiology, or functionality.

Abstract: The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.

Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.

Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Abstract: This invention relates to methods and compositions for assessing risk by measuring total and specific cell-free nucleic acids (such as DNA) in a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant rejection.

Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having a combination of G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.

Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant rejection, in subject.

Abstract: A compression device is used to increase intra-luminal pressure within the upper esophageal sphincter of a patient in order relieve an impact of an abnormal or defective upper esophageal sphincter anatomy, physiology, or functionality. In one implementation, the compression device is used in conjunction with an external pressure sensing device to determine the external pressure that is to be applied to the cricoid for a specific patient. The compression device can be a means for the management and/or treatment of abnormal upper esophageal sphincter functionality, or a means for strengthening an esophageal sphincter of a subject, or a means for curing esophageal reflux disease of a subject, or a means for improving vocal function in a subject, or a means for managing lung aspiration, or a means for applying cricoid pressure during anesthesia intubation, or a means for stabilizing body structures such as during medical imaging or radiation treatment.

Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.

Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.

Abstract: Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.

Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition in a subject.

Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a pregnant subject with the non-native nucleic acids being fetal specific. The methods and compositions provided herein can be used to determine risk of a condition, such as a fetal condition, in a pregnant subject.

Abstract: Systems and methods directed to adaptive radiotherapy planning are provided. In some aspects, provided system and method include producing synthetic images from magnetic resonance data using relaxometry maps. The method includes applying corrections to the data and generating relaxometry maps therefrom. In other aspects, a method for adapting a radiotherapy plan is provided. The method includes determining an objective function based on dose gradients from an initial dose distribution, and generating an optimized plan based on updated images, using aperture morphing and gradient maintenance algorithms without need for organ-at-risk contouring.

Abstract: Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).

Abstract: A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end. The one or more wires extend through the elongated catheter shaft and are situated adjacent the magnetic sensor. Each of the one or more wires is electrically coupled to the coil at the coil distal end.